Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
77
MIRM Quote, Financials, Valuation and Earnings
Last price:
$80.69
Seasonality move
:
3.77%
Day range:
$78.87 - $81.09
52-week range:
$36.88 - $82.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.72x
P/B ratio:
14.21x
Volume:
241.9K
Avg. volume:
763.2K
1-year change:
91.49%
Market cap:
$4.2B
Revenue:
$336.9M
EPS (TTM):
-$0.86
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$130.5M | -$0.16 | 36.59% | -85.85% | $103.10 |
|
ADMA
ADMA Biologics, Inc.
|
$130.5M | $0.16 | 18.97% | -56.04% | $25.67 |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$87M | -$0.09 | 53.91% | -88.43% | $31.63 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
INSM
Insmed, Inc.
|
$115.5M | -$1.37 | 66.86% | -2.57% | $214.78 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -4.58% | 694.41% | $28.62 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$80.75 | $103.10 | $4.2B | -- | $0.00 | 0% | 8.72x |
|
ADMA
ADMA Biologics, Inc.
|
$19.53 | $25.67 | $4.6B | 22.93x | $0.00 | 0% | 9.83x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$29.44 | $31.63 | $3.6B | -- | $0.00 | 0% | 11.83x |
|
CRMD
CorMedix, Inc.
|
$12.19 | $19.00 | $960.4M | 5.94x | $0.00 | 0% | 4.10x |
|
INSM
Insmed, Inc.
|
$177.42 | $214.78 | $37.8B | -- | $0.00 | 0% | 75.50x |
|
PFE
Pfizer Inc.
|
$25.03 | $28.62 | $142.3B | 14.59x | $0.43 | 6.87% | 2.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MIRM
Mirum Pharmaceuticals, Inc.
|
52.19% | 1.763 | 8.47% | 3.01x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -2.565 | 2.38% | 3.53x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
41.85% | -0.694 | 5.02% | 3.07x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
INSM
Insmed, Inc.
|
44.07% | 2.512 | 2.43% | 4.18x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$107.4M | $2.6M | -7.32% | -16.73% | 1.96% | $39.5M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$90.5M | $8.5M | -15.75% | -29.4% | 8.59% | -$1.8M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
Mirum Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns MIRM or ADMA?
ADMA Biologics, Inc. has a net margin of 2.18% compared to Mirum Pharmaceuticals, Inc.'s net margin of 27.14%. Mirum Pharmaceuticals, Inc.'s return on equity of -16.73% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital MIRMMirum Pharmaceuticals, Inc.80.75% $0.05 $610.8M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About MIRM or ADMA?
Mirum Pharmaceuticals, Inc. has a consensus price target of $103.10, signalling upside risk potential of 27.68%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 31.69%. Given that ADMA Biologics, Inc. has higher upside potential than Mirum Pharmaceuticals, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Mirum Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MIRMMirum Pharmaceuticals, Inc.8 0 0 ADMAADMA Biologics, Inc.3 0 0 -
Is MIRM or ADMA More Risky?
Mirum Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.855% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.
-
Which is a Better Dividend Stock MIRM or ADMA?
Mirum Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIRM or ADMA?
Mirum Pharmaceuticals, Inc. quarterly revenues are $133M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Mirum Pharmaceuticals, Inc.'s net income of $2.9M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 22.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals, Inc. is 8.72x versus 9.83x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRMMirum Pharmaceuticals, Inc.8.72x -- $133M $2.9M ADMAADMA Biologics, Inc.9.83x 22.93x $134.2M $36.4M
-
Which has Higher Returns MIRM or ARQT?
Arcutis Biotherapeutics, Inc. has a net margin of 2.18% compared to Mirum Pharmaceuticals, Inc.'s net margin of 7.47%. Mirum Pharmaceuticals, Inc.'s return on equity of -16.73% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.
Company Gross Margin Earnings Per Share Invested Capital MIRMMirum Pharmaceuticals, Inc.80.75% $0.05 $610.8M ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M -
What do Analysts Say About MIRM or ARQT?
Mirum Pharmaceuticals, Inc. has a consensus price target of $103.10, signalling upside risk potential of 27.68%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 7.9%. Given that Mirum Pharmaceuticals, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe Mirum Pharmaceuticals, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MIRMMirum Pharmaceuticals, Inc.8 0 0 ARQTArcutis Biotherapeutics, Inc.5 1 0 -
Is MIRM or ARQT More Risky?
Mirum Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.855% less volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.693, suggesting its more volatile than the S&P 500 by 69.345%.
-
Which is a Better Dividend Stock MIRM or ARQT?
Mirum Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIRM or ARQT?
Mirum Pharmaceuticals, Inc. quarterly revenues are $133M, which are larger than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. Mirum Pharmaceuticals, Inc.'s net income of $2.9M is lower than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals, Inc. is 8.72x versus 11.83x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRMMirum Pharmaceuticals, Inc.8.72x -- $133M $2.9M ARQTArcutis Biotherapeutics, Inc.11.83x -- $99.2M $7.4M
-
Which has Higher Returns MIRM or CRMD?
CorMedix, Inc. has a net margin of 2.18% compared to Mirum Pharmaceuticals, Inc.'s net margin of 49.9%. Mirum Pharmaceuticals, Inc.'s return on equity of -16.73% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital MIRMMirum Pharmaceuticals, Inc.80.75% $0.05 $610.8M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About MIRM or CRMD?
Mirum Pharmaceuticals, Inc. has a consensus price target of $103.10, signalling upside risk potential of 27.68%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 55.87%. Given that CorMedix, Inc. has higher upside potential than Mirum Pharmaceuticals, Inc., analysts believe CorMedix, Inc. is more attractive than Mirum Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MIRMMirum Pharmaceuticals, Inc.8 0 0 CRMDCorMedix, Inc.4 0 0 -
Is MIRM or CRMD More Risky?
Mirum Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.855% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock MIRM or CRMD?
Mirum Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIRM or CRMD?
Mirum Pharmaceuticals, Inc. quarterly revenues are $133M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Mirum Pharmaceuticals, Inc.'s net income of $2.9M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals, Inc. is 8.72x versus 4.10x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRMMirum Pharmaceuticals, Inc.8.72x -- $133M $2.9M CRMDCorMedix, Inc.4.10x 5.94x $104.3M $108.6M
-
Which has Higher Returns MIRM or INSM?
Insmed, Inc. has a net margin of 2.18% compared to Mirum Pharmaceuticals, Inc.'s net margin of -259.95%. Mirum Pharmaceuticals, Inc.'s return on equity of -16.73% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital MIRMMirum Pharmaceuticals, Inc.80.75% $0.05 $610.8M INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About MIRM or INSM?
Mirum Pharmaceuticals, Inc. has a consensus price target of $103.10, signalling upside risk potential of 27.68%. On the other hand Insmed, Inc. has an analysts' consensus of $214.78 which suggests that it could grow by 21.15%. Given that Mirum Pharmaceuticals, Inc. has higher upside potential than Insmed, Inc., analysts believe Mirum Pharmaceuticals, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MIRMMirum Pharmaceuticals, Inc.8 0 0 INSMInsmed, Inc.17 1 0 -
Is MIRM or INSM More Risky?
Mirum Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.855% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.
-
Which is a Better Dividend Stock MIRM or INSM?
Mirum Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIRM or INSM?
Mirum Pharmaceuticals, Inc. quarterly revenues are $133M, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Mirum Pharmaceuticals, Inc.'s net income of $2.9M is higher than Insmed, Inc.'s net income of -$370M. Notably, Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals, Inc. is 8.72x versus 75.50x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRMMirum Pharmaceuticals, Inc.8.72x -- $133M $2.9M INSMInsmed, Inc.75.50x -- $142.3M -$370M
-
Which has Higher Returns MIRM or PFE?
Pfizer Inc. has a net margin of 2.18% compared to Mirum Pharmaceuticals, Inc.'s net margin of 21.32%. Mirum Pharmaceuticals, Inc.'s return on equity of -16.73% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital MIRMMirum Pharmaceuticals, Inc.80.75% $0.05 $610.8M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About MIRM or PFE?
Mirum Pharmaceuticals, Inc. has a consensus price target of $103.10, signalling upside risk potential of 27.68%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.36%. Given that Mirum Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Mirum Pharmaceuticals, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings MIRMMirum Pharmaceuticals, Inc.8 0 0 PFEPfizer Inc.7 15 1 -
Is MIRM or PFE More Risky?
Mirum Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.855% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock MIRM or PFE?
Mirum Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. Mirum Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios MIRM or PFE?
Mirum Pharmaceuticals, Inc. quarterly revenues are $133M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Mirum Pharmaceuticals, Inc.'s net income of $2.9M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals, Inc. is 8.72x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRMMirum Pharmaceuticals, Inc.8.72x -- $133M $2.9M PFEPfizer Inc.2.28x 14.59x $16.7B $3.6B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
